Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_assertion type Assertion NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_head.
- NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_assertion description "[Despite this apparent success, the development of clinical resistance to imatinib therapy, and the inability of imatinib to eradicate BCR-ABL-positive malignant hematopoietic progenitors demand detailed investigations of additional effector pathways that can be targeted for CML treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_provenance.
- NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_assertion evidence source_evidence_literature NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_provenance.
- NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_assertion SIO_000772 17980712 NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_provenance.
- NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_assertion wasDerivedFrom befree-2016 NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_provenance.
- NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_assertion wasGeneratedBy ECO_0000203 NP638620.RABTbapXMgPCtvdcgCfFizv7hMB3wclejKTzNK6O1xCWA130_provenance.